Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Sirtuin-1 deacetylates proteins and has emerged as a critical regulator of different cellular processes, particularly inflammation. Basal SIRT1 activity was previously found to limit Th9 and enhance Th17 differentiation in mice, but the effect of pharmacological SIRT1 activation on T cell differentiation and antitumor responses remains unclear. Here, we find that SIRT1 pharmacological agonists selectively impede mouse and human Th17 cell differentiation. SIRT1 activation induces STAT3 deacetylation, thus reducing its ability to translocate into the nucleus, bind to Rorc promoter, and induce its transcription. SIRT1 agonists reduce tumor growth in mice by blocking Th17 cell differentiation. In cancer patients, the SIRT1 agonist metformin reduced the frequency of Th17 cells and STAT3 acetylation levels. Altogether, these data underscore that SIRT1 activation impedes Th17 cell differentiation and thereby limits tumor growth and suggest that SIRT1 activators may directly target IL-17A functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 1×
“Th17 cells are characterized by their capacity to secrete IL-17A, IL-17F, IL-21, IL-22, and CCL20 (Dong, 2008; Liang et al., 2006).”
BackgroundWen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 1×
“Th17 cells are characterized by their capacity to secrete IL-17A, IL-17F, IL-21, IL-22, and CCL20 (Dong, 2008; Liang et al., 2006).”
BackgroundStat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · cited 1×
“This modification is required for STAT3 dimerization, phosphorylation of tyrosine 705, and transcriptional function (Nie et al., 2009; Yuan et al., 2005).”
BackgroundChalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Self-citationSong, Y. M., Lee, Y.-H., Kim, J.-W., Ham, D.-S., Kang, E.-S., Cha, B. S., Lee, H. C., & Lee, B.-W. (2015) · Autophagy · doi:10.4161/15548627.2014.984271 · Cited by 332
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant
Chandel, N. S., Avizonis, D., Reczek, C. R., Weinberg, S. E., Menz, S., Neuhaus, R., Christian, S., Haegebarth, A., Algire, C., & Pollak, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.010 · Cited by 176 · cited 1×
“A lower dosage of metformin of 10 mM equivalent to the dosage classically found in mouse serum (Chandel et al., 2016) also impedes the in vitro Th17 differentiation (Figure S1B).”
BackgroundYin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016) · Medicine · doi:10.1097/md.0000000000002749 · Cited by 59 · cited 1×
“Notably, it has been shown that cancer rates in diabetics using metformin are lower than in patients using other insulin-sensitizing agents or insulin (Chlebowski et al., 2012; Gong et al., 2016; He et al., 2016).”
Background
Cited by
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Catalkaya, G., Venema, K., Lucini, L., Rocchetti, G., Delmas, D., Daglia, M., De Filippis, A., Xiao, H., Quiles, J. L., Xiao, J., et al. (2020) · Food Frontiers · doi:10.1002/fft2.25 · Cited by 328
Self-citationImmunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
STAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
“Th17 KO STAT3 Inhibition of Differentiation [29,30] IL-6, IL-21, IL-23 ↗ RORγt and RORα→ Differentiation (↗ IL-17) [31–35] PPARγ ligand, Platelet factor 4 ↗ SOCS3→ Inhibition of Differentiation [36] SHP1 ↘ pSTAT3→ Inhibition of Differentiation [37] LOXL3 ↘ STAT3 deacetylation→ Differentiation [38] Metformin, Resveratr…”
BackgroundSelf-citationMetformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation
Cuyàs, E., Verdura, S., Llorach-Parés, L., Fernández-Arroyo, S., Joven, J., Martin-Castillo, B., Bosch-Barrera, J., Brunet, J., Nonell-Canals, A., Sanchez-Martinez, M., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00657 · Cited by 122
SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism
Varghese, B., Chianese, U., Capasso, L., Sian, V., Bontempo, P., Conte, M., Benedetti, R., Altucci, L., Carafa, V., & Nebbioso, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04440-9 · Cited by 31
“SIRT1 is significantly expressed in HCC cell lines and tumor tissues [42] and facilitates metastasis [43], while pharmacological SIRT1 activation was found to limit cancer growth in mouse models [44].”
BackgroundCourtaut, F., Scagliarini, A., Aires, V., Cornebise, C., Pais de Barros, J.-P., Olmiere, C., & Delmas, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126590 · Cited by 17
Self-citation
Metadata
- Authors
- Limagne, E., Thibaudin, M., Euvrard, R., Berger, H., Chalons, P., Végan, F., Humblin, E., Boidot, R., Rébé, C., Derangère, V., Ladoire, S., Apetoh, L., Delmas, D., & Ghiringhelli, F.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 19
- Issue
- 4
- Pages
- 746-759
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2610072177
- Cited by
- 138
- References
- 10
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.